Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study.
Fanny De La FuenteRakiba BelkhirJulien HenryChi Duc NguyenThao PhamVincent GermainPierre Edouard GavandCéline LabadieClaire BriereAmbre LauretThierry CardonGael MouterdeIsabelle BonnetLéa RouxelMarie-Elise TruchetetThierry SchaeverbekeChristophe RichezMarie Kostinenull nullPublished in: RMD open (2022)
Anti-IL-6R therapy is currently the most common strategy in patients with ICI-induced inflammatory arthritis and insufficient response to glucocorticoids and methotrexate, leading to improvement in >80%. Overall, cancer progression occurred in about half of patients and whether the bDMARD/JAKi impacted the tumour response remains to be determined.
Keyphrases
- end stage renal disease
- rheumatoid arthritis
- oxidative stress
- newly diagnosed
- ejection fraction
- chronic kidney disease
- dna damage
- peritoneal dialysis
- cell cycle
- high glucose
- stem cells
- diabetic rats
- cell proliferation
- patient reported outcomes
- mesenchymal stem cells
- drug induced
- bone marrow
- endothelial cells
- stress induced